A person can feel perfectly healthy while fat gradually accumulates inside his liver.
There may be no pain, no dramatic change in appearance and no obvious warning that anything is wrong. Yet metabolic dysfunction-associated steatotic liver disease, or MASLD, has become one of the most common chronic liver conditions in the United States.
Current estimates cited by the American Association for the Study of Liver Diseases put U.S. prevalence at roughly 33.7% of adults, meaning approximately one in three may be affected. The same projections suggest prevalence could climb above 40% by 2050 if current metabolic-health trends continue.
That is what makes the disease particularly concerning.
MASLD can remain silent for years while some patients gradually develop inflammation and liver scarring. By the time symptoms become obvious, the disease may be considerably more advanced.
What Exactly Is MASLD?
MASLD is the newer name for what many people still know as nonalcoholic fatty liver disease, or NAFLD.
The terminology changed because doctors wanted the name to better reflect what actually drives the condition. MASLD describes fat accumulation in the liver occurring alongside at least one cardiometabolic risk factor, such as obesity, abnormal blood sugar, high blood pressure or unhealthy blood-fat levels.
The American Association for the Study of Liver Diseases explains that MASLD is now the preferred term and describes it as the world’s most common chronic liver disease.
A healthy liver normally contains some fat.
The problem develops when excessive amounts accumulate.
For many people, the disease remains at the relatively simple fatty-liver stage. In others, however, the liver develops inflammation and cellular injury. That more serious form is known as metabolic dysfunction-associated steatohepatitis, or MASH.
MASH can eventually lead to fibrosis, cirrhosis and other serious liver complications.
Why Can Someone Have Liver Disease Without Knowing It?
The liver is unusually good at continuing to work despite damage.
That is useful for survival.
It is less useful for early diagnosis.
The National Institute of Diabetes and Digestive and Kidney Diseases describes MASLD as a silent disease because people commonly experience few or no symptoms. Remarkably, some individuals can remain without obvious symptoms even after significant liver damage has developed.
When symptoms do occur, they may be nonspecific.
A person may feel tired or experience discomfort around the upper-right side of his abdomen, but those symptoms can have many possible causes.
That means MASLD is frequently discovered accidentally.
A routine blood test may show abnormal liver enzymes.
An ultrasound performed for another reason may reveal fat in the liver.
Or a doctor may investigate because the patient has diabetes, obesity or another metabolic risk factor.
The absence of symptoms therefore does not necessarily mean the liver is healthy.
The Disease Is Closely Connected With America’s Metabolic Health
MASLD has become increasingly common alongside obesity, type 2 diabetes and metabolic syndrome.
That relationship is not accidental.
When the body becomes resistant to insulin and has difficulty managing excess energy, more fatty acids can accumulate in the liver.
The NIDDK says obesity, metabolic syndrome and type 2 diabetes are all important risk factors. Its research also estimates that up to 70% of people with type 2 diabetes may have fatty liver disease, although many do not know it.
That is a remarkably high overlap.
The Mayo Clinic’s explanation of metabolic syndrome describes a cluster that includes high blood sugar, high blood pressure, abnormal cholesterol or triglycerides and excess fat around the waist.
The liver is increasingly understood as one of the organs affected by that same metabolic dysfunction.
MASLD therefore is not simply a “liver problem.”
It can be a visible consequence of a much broader metabolic problem affecting the entire body.
Not Everyone With Fatty Liver Develops Cirrhosis
The one-in-three statistic sounds frightening, but an important distinction is necessary.
Most people with MASLD will not automatically progress to liver failure.
The disease exists on a spectrum.
Some people have fat accumulation without substantial inflammation or scarring and may remain relatively stable for years.
Others develop MASH.
Among those patients, fibrosis can progressively replace healthy liver tissue with scar tissue.
Advanced fibrosis can eventually become cirrhosis, where the liver’s normal structure and function are seriously disrupted. MASLD and MASH can also increase the risk of hepatocellular carcinoma, the most common form of primary liver cancer.
Doctors therefore care greatly about fibrosis, not simply whether fat is present.
AASLD describes the degree of liver fibrosis as one of the most important predictors of liver-related illness and mortality.
The central clinical question becomes: which patients are simply carrying excess liver fat, and which are quietly progressing toward serious scarring?
A Normal-Looking Person Can Still Be at Risk
Obesity is a major risk factor, but it is not the only one.
A person does not need to look severely overweight to develop MASLD.
Genetics, fat distribution, insulin resistance, diet, ethnicity and other metabolic factors can influence risk.
Someone may carry relatively little visible fat while accumulating more harmful visceral fat around internal organs.
That is why appearance alone is a poor screening tool.
A person who looks healthy but has type 2 diabetes, high triglycerides, hypertension or abnormal blood sugar may still deserve evaluation based on his overall risk profile.
The newer MASLD terminology emphasizes precisely this metabolic connection instead of focusing primarily on whether the patient drinks alcohol.
Doctors Do Not Need a Liver Biopsy for Everyone
Traditionally, a liver biopsy has provided the most detailed way to examine liver inflammation and fibrosis.
But biopsies are invasive and carry small but genuine risks.
Modern medicine increasingly uses noninvasive tools to determine who needs more extensive investigation.
One commonly used calculation is called FIB-4. It combines a patient’s age with routine laboratory results including AST, ALT and platelet count to estimate the probability of advanced fibrosis.
If further evaluation is needed, doctors may use specialized imaging such as vibration-controlled transient elastography, often associated with the FibroScan name, to measure liver stiffness.
The NIDDK overview of MASLD diagnosis explains how blood tests, imaging and, in selected circumstances, biopsy can be used to assess fatty liver disease.
This staged approach matters because screening every American with expensive imaging would be impractical.
The goal is identifying people most likely to have dangerous fibrosis.
Weight Loss Can Produce Meaningful Changes in the Liver
One of the most encouraging things about MASLD is that early disease is not necessarily a one-way journey.
Lifestyle changes can reduce liver fat.
AASLD notes evidence that losing more than 5% of body weight can reduce hepatic steatosis, while larger weight reductions may produce improvements in inflammation and, in some patients, fibrosis.
That does not mean every patient should follow the same diet or chase one specific number on a scale.
Treatment needs to account for age, muscle mass, diabetes, cardiovascular health and the severity of liver disease.
Exercise matters even without dramatic weight loss.
Research summarized by AASLD supports regular physical activity because it can improve liver and metabolic measures, while also providing cardiovascular benefits.
The NIDDK’s nutrition guidance for fatty liver disease also emphasizes healthy eating patterns and appropriate weight management.
The important point is consistency rather than extreme dieting.
The Heart May Be Just as Important as the Liver
MASLD creates another paradox.
Someone diagnosed with fatty liver may naturally assume his liver is the only organ requiring attention.
Yet cardiovascular disease is a major health threat among people with metabolic fatty liver disease.
That makes management of blood pressure, blood sugar, cholesterol, physical activity and smoking status extremely important. AASLD specifically emphasizes cardiovascular benefits when discussing exercise and metabolic management in people with fatty liver disease.
This makes MASLD a useful warning signal.
A fatty liver can indicate that metabolic dysfunction is affecting the body more broadly.
Treating the patient rather than simply treating a liver-enzyme number therefore matters.
Why the “One in Three” Number Could Still Rise
AASLD projections estimate that U.S. MASLD prevalence could increase from about 33.7% to 41.4% by 2050, potentially affecting around 121.9 million people.
Other epidemiological research places current global adult prevalence even higher, at roughly 38%, and projects substantial further increases as obesity and type 2 diabetes become more common.
Exact estimates differ because researchers use different populations and diagnostic definitions.
The direction is much less controversial.
MASLD is becoming more common.
That is why physicians increasingly want primary-care systems to identify higher-risk individuals before cirrhosis develops.
Waiting for symptoms defeats much of the advantage.
Silent Does Not Mean Harmless
The frightening thing about MASLD is not that one-third of American adults are about to experience liver failure.
They are not.
It is that a very common disease can exist unnoticed while a smaller but medically important group gradually progresses toward inflammation and scarring.
Someone may feel well.
He may work normally.
He may never experience obvious liver pain.
Yet metabolic dysfunction can continue changing his liver in the background.
That is why people with diabetes, obesity and other metabolic risk factors should discuss appropriate liver-risk assessment with their healthcare professionals rather than relying on symptoms alone.
For most people, the answer will not involve panic or an invasive procedure.
It may begin with routine medical history, laboratory tests and assessment of metabolic risk.
The liver has an extraordinary ability to tolerate stress.
That resilience helps explain why MASLD can stay hidden for so long.
But it creates a dangerous misunderstanding too.
A disease does not have to hurt before it matters.
